Thrombophlebitis

Summary

Thrombophlebitis (MONDO:0002800) is a disease and 10 clinical trials. Top therapeutic interventions include warfarin and sesame oil. A subtype of phlebitis — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 10

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	thrombophlebitis
Mondo ID	MONDO:0002800
MeSH	D013924
DOID	DOID:3875
ICD-10-CM	I80.0
NCIT	C3410
SNOMED CT	40283005
UMLS	C0040046
MedGen	11799
Is cancer (heuristic)	no

Also known as: phlebitis and thrombophlebitis of superficial vessels of lower extremities

Disease family

This is a subtype of phlebitis. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › cardiovascular disorder › vascular disorder › vein disorder › phlebitis › thrombophlebitis

Subtypes (3): iliac vein thrombophlebitis, femoral vein thrombophlebitis, thrombophlebitis migrans

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

Drugs indicated for this disease

1 approved, 1 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.

Drug	Development status
Zinc Oxide	Approved (phase 4)
Parnaparin Sodium	Phase 3 (in late-stage trials)

Clinical trials & evidence

Clinical trials

Clinical trials: 10.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	6
PHASE3	3
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00000517	PHASE3	COMPLETED	Boston Area Anticoagulation Trial for Atrial Fibrillation (BAATAF)
NCT00362947	PHASE3	COMPLETED	Different Doses and Duration of Low Molecular Weight Heparin (Parnaparin)in Superficial Vein Thrombosis
NCT01943006	PHASE3	COMPLETED	Efficacy and Tolerability of Hirudoid Cream in Prophylaxis and Treatment Infusion Phlebitis
NCT00001713	PHASE1	COMPLETED	Treatment for Blood Clots in the Veins of the Legs
NCT07524608	Not specified	NOT_YET_RECRUITING	Implementing an Evidence-based, Standardized Care Bundle Targeting Register Nurses and Anaesthesiologists, to Enhance Patient Safety and Quality of Intravascular Access Devices Care Management - The Safe-IVADs Project. A Longitudinell Implementation Intervention With an Embedded Process Evaluation.
NCT00818688	Not specified	COMPLETED	POST (Prospective Observational Superfial Thrombophlebitis)
NCT04338932	Not specified	COMPLETED	COVID-19 and Deep Venous Thrombosis
NCT06216522	Not specified	COMPLETED	The Effectiveness of Topical Sesame Oil in Preventing Phlebitis at IV Cannula Sites in Adults
NCT06415968	Not specified	TERMINATED	Prevalence and Characteristics of Intimate Partner Violence Against Individuals Seeking Hematological Consultations
NCT07182877	Not specified	COMPLETED	Comparison of Dwell Time of Open Versus Closed Type Peripheral Intravenous Cannula

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
WARFARIN	4	2
SESAME OIL	3	1